Induced Pluripotent Stem Cells Help Eisai's Hunt For Novel Parkinson's Leads
As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.
You may also be interested in...
18-month Phase II data on amyloid-targeting antibody BAN2401, presented at AAIC, raised more questions than they answered – and seemed to take the wind out of the sails for an early regulatory filing.
Amid multiple industry drug failures in the sector, Eisai is opening a new US research facility to discover innovative therapies for dementia based on a long-standing immunology hypothesis.
Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.